Biological and predictive role of ERCC1 polymorphisms in cancer

被引：16

作者：

Formica, V. ^{[1
]}

Doldo, E. ^{[2
]}

Antonetti, F. R. ^{[1
]}

Nardecchia, A. ^{[1
]}

Ferroni, P. ^{[3
]}

Riondino, S. ^{[1
,3
]}

Morelli, C. ^{[1
]}

Arkenau, H. T. ^{[4
]}

Guadagni, F. ^{[3
]}

Orlandi, A. ^{[2
]}

Roselli, M. ^{[1
]}

机构：

[1] Tor Vergata Clin Ctr Univ Hosp, Dept Syst Med, Med Oncol Unit, Viale Oxford 81, I-00133 Rome, Italy

[2] Tor Vergata Univ Hosp, Inst Pathol Anat, Dept Biomed & Prevent, Rome, Italy

[3] San Raffaele Roma Open Univ, Dept Human Sci & Qual Life Promot, Rome, Italy

[4] Sarah Cannon Res Inst, Drug Dev Unit, London, England

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2017年 / 111卷

关键词：

ERCC1; Oxaliplatin; Single nucleotide polymorphisms; Colorectal cancer; NUCLEOTIDE EXCISION-REPAIR; ADVANCED COLORECTAL-CANCER; RELATIVE DOSE INTENSITY; MESSENGER-RNA LEVELS; GENE-SPECIFIC REPAIR; DNA-REPAIR; ADJUVANT CHEMOTHERAPY; XERODERMA-PIGMENTOSUM; OXALIPLATIN; CISPLATIN;

D O I：

10.1016/j.critrevonc.2017.01.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Excision repair cross-complementation group 1 (ERCCI) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. Germline ERCCI polymorphisms may alter the protein expression and published data on their predictive and prognostic value have so far been contradictory. In the present article we review available evidence on the clinical role and utility of ERCC1 polymorphisms and, in the absence of a 'perfect' trial, what we call the 'sliding doors' trial, we present the data of ERCC1 genotyping in our local patient population. We found a useful predictive value for oxaliplatin-induced risk of anemia. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：133 / 143

页数：11

共 50 条

[1] Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome
Huang, Ming-Yii
Wang, Jaw-Yuan
Huang, Meng-Lin
Chang, Hui-Jen
Lin, Shiu-Ru
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (02): : 4121 - 4134
[2] ERCC1 and lung cancer
Planchard, D.
Olaussen, K. -A.
Soria, J. -C.
REVUE DES MALADIES RESPIRATOIRES, 2010, 27 (04) : 387 - 394
[3] Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody
Smith, David Hersi
Fiehn, Anne-Marie Kanstrup
Fogh, Louise
Christensen, Ib Jarle
Hansen, Tine Plato
Stenvang, Jan
Nielsen, Hans Jorgen
Nielsen, Kirsten Vang
Hasselby, Jane Preuss
Brunner, Nils
Jensen, Sussie Steen
SCIENTIFIC REPORTS, 2014, 4
[4] ERCC1 expression in triple negative breast cancer
Ozkan, C.
Gumuskaya, B.
Yaman, S.
Aksoy, S.
Guler, G.
Altundag, K.
JOURNAL OF BUON, 2012, 17 (02): : 271 - 276
[5] ERCC1 and RRM1 genes in lung cancer
Carvalho, Lina
Silva, Antonio
Andrade, Claudia
Barroso, Claudia
Farinha, Claudia
Fernandes, Jose Carlos
Landeiro, Raquel
REVISTA PORTUGUESA DE PNEUMOLOGIA, 2009, 15 (04) : 683 - 696
[6] Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer
He, M. G.
Zheng, K.
Tan, D.
Wang, Z. X.
GENETICS AND MOLECULAR RESEARCH, 2016, 15 (01): : 1 - 7
[7] Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer
Yang, H.
Li, G.
Li, W. F.
GENETICS AND MOLECULAR RESEARCH, 2015, 14 (01) : 700 - 705
[8] Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy
Jiang, Hong
Li, Baosong
Wang, Fengxia
Ma, Chong
Hao, Tao
ONCOLOGY LETTERS, 2019, 18 (02) : 1157 - 1162
[9] Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort
Bao, Yuxia
Yang, Bin
Zhao, Jingjiao
Shen, Simin
Gao, Jianyuan
INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2020, 47 (05) : 443 - 453
[10] ERCC1: impact in multimodality treatment of upper gastrointestinal cancer
Metzger, Ralf
Bollschweiler, Elfriede
Hoelscher, Arnulf H.
Warnecke-Eberz, Ute
FUTURE ONCOLOGY, 2010, 6 (11) : 1735 - 1749

← 1 2 3 4 5 →